Ipamorelin 2mg

Ipamorelin 2 mg

Manufacturer: Euro-Pharmacies
Package: 2 mg/vial
Dosage: 2 mg
Common Names: Ipamorelin 2 mg, Ipamorelin, (EP) Ipamorelin, Ipamorelin Peptide, Growth Hormone Secretagogue Peptide

Info: (EP) Ipamorelin 2 mg from Euro-Pharmacies contains Ipamorelin, a synthetic pentapeptide belonging to the class of growth hormone secretagogues. It acts as an agonist of the ghrelin receptor (GHS-R1a), stimulating the release of endogenous growth hormone from the pituitary gland. Ipamorelin has been investigated for its relatively selective effect on growth hormone secretion compared with certain other secretagogues. It remains an investigational compound without an established approved therapeutic indication for routine human use.

Effects

Growth Hormone Stimulation: Ipamorelin activates the ghrelin receptor and has been studied for its ability to stimulate endogenous growth hormone release.

Selective Hormonal Activity: Research has examined its relatively selective effect on growth hormone secretion and its potentially limited influence on cortisol and prolactin compared with some other growth hormone secretagogues. Further clinical evidence is required to characterize these effects fully.

Side Effects

Potential concerns associated with Ipamorelin include headache, dizziness, and localized reactions such as redness, swelling, or tenderness following injection. Changes in growth hormone signaling may influence fluid balance and glucose metabolism. Repeated exposure may also affect growth hormone and IGF-1 levels. Hypersensitivity reactions are possible, while the frequency and clinical significance of these effects remain insufficiently characterized. Long-term human safety data are limited.

Dosage Range and Duration of Use

(Ipamorelin 2 mg contains a stated total quantity of 2 mg of Ipamorelin per vial in a lyophilized powder formulation. Under controlled clinical research and experimental protocols, research dosages typically range from 100 mcg to 300 mcg per administration, delivered via subcutaneous injection 1 to 3 times daily (most commonly prior to sleep or in a fasted state). Experimental research protocols generally span a duration of 8 to 12 weeks to assess growth hormone pulse dynamics and metabolic markers without inducing desensitization of the ghrelin receptor.

Combination with Other Drugs

Ipamorelin has been investigated in relation to growth hormone signaling and the GH/IGF-1 pathway. Combining it with other growth hormone secretagogues or hormonal compounds may introduce additional uncertainties regarding endocrine effects, glucose regulation, and fluid balance. Reliable clinical evidence establishing the safety and efficacy of specific combinations is insufficient. Potential interactions with prescription medicines and other compounds should be evaluated by a qualified healthcare professional.